Witnessing the stock’s movement on the chart, on Wednesday, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) set off with pace as it heaved 5.16% to $170.81, before settling in for the price of $162.43 at the close. Taking a more long-term approach, JAZZ posted a 52-week range of $95.49-$182.99.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -1.00%. Meanwhile, its Annual Earning per share during the time was -1.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -62.16%. This publicly-traded company’s shares outstanding now amounts to $60.74 million, simultaneously with a float of $57.98 million. The organization now has a market capitalization sitting at $10.38 billion.
Jazz Pharmaceuticals plc (JAZZ) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Jazz Pharmaceuticals plc’s current insider ownership accounts for 4.58%, in contrast to 100.57% institutional ownership. According to the most recent insider trade that took place on Dec 09 ’25, this organization’s SVP, Technical Operations sold 2,238 shares at the rate of 169.51, making the entire transaction reach 379,366 in total value, affecting insider ownership by 19,508.
Jazz Pharmaceuticals plc (JAZZ) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.15 per share during the current fiscal year.
Jazz Pharmaceuticals plc’s EPS decrease for this current 12-month fiscal period is -62.16% and is forecasted to reach 22.50 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 6.10% through the next 5 years, which can be compared against the -1.00% growth it accomplished over the previous five years trading on the market.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Trading Performance Indicators
Let’s observe the current performance indicators for Jazz Pharmaceuticals plc (JAZZ). It’s Quick Ratio in the last reported quarter now stands at 1.44. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.50. Similarly, its price to free cash flow for trailing twelve months is now 7.77.
In the same vein, JAZZ’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -6.07, a figure that is expected to reach 6.39 in the next quarter, and analysts are predicting that it will be 22.50 at the market close of one year from today.
